Pierre Sokoloff

Pierre Sokoloff has a diverse and extensive work experience in the field of biotechnology and research. Pierre'smost recent role was as the Chief Scientific Officer and co-founder of BIODOL THERAPEUTICS, a biotech company focusing on the development of compounds for chronic pain treatment. During their time there, Pierre played a key role in the discovery and understanding of the target protein FLT3, which is involved in neuropathic pain. Pierre also contributed to research on using the FLT3 platform to combat the opioid crisis. Pierre Sokoloff founded and served as the CEO of PSAdvice, a company they ran from 2015 to 2020. Prior to their entrepreneurial endeavors, they held various positions at reputable organizations such as the Pierre Fabre Research Institute, where they led the CNS Exploratory R&D team for a decade. Before that, they worked as a Director at CNRS and led the Neurobiology and Molecular Pharmacology group at INSERM U 109. Throughout their career, Pierre has made significant contributions as a group leader, research fellow, senior researcher, and researcher.

Pierre Sokoloff obtained their Diploma of Biochemistry Engineer from the National Institute of Applied Sciences in Lyon, France in 1977. Later, they pursued a Doctorate/PhD in Molecular Pharmacology at the Université Pierre et Marie Curie in Paris, France and completed it in 1981. No specific information is available about their educational activities prior to 1972 or after 1981.